EFFICACY OF PENTOXIFYLLINE AS AN ANTIFIBROTIC DRUG IN EXPERIMENTAL MURINE SCHISTOSOMAL HEPATIC FIBROSIS

KHALIFA, EMAN A.; NEMENQANI, DALAL M.

doi:10.21608/jesp.2014.90404

EFFICACY OF PENTOXIFYLLINE AS AN ANTIFIBROTIC DRUG IN EXPERIMENTAL MURINE SCHISTOSOMAL HEPATIC FIBROSIS

Document Type : Original Article

Authors

¹ Department of Microbiology, Faculty of Medicine, Taif University, Taif, Kingdom of Saudi Arabia.

² Department of Pathology, Faculty of Medicine, Taif University, Taif, Kingdom of Saudi Arabia.

10.21608/jesp.2014.90404

Abstract

This study evaluated the possible antifibrotic effect of pentoxifylline on experimentally induced schistosomal hepatic fibrosis and its effect on serum leptin and transforming growth factor- β1 levels as possible antifibrotic mechanisms in correlation with the hepatic fibrosis indices. A total of ninety clean laboratories bred, males Swiss, albino mice were included, of which ten mice served as a control non-infected, non-treated group and sacrificed at one time. Eighty mice, each was subcutaneously infected with 50 Schistosoma mansoni cercariae and classified into groups: GI (infected & non-treated), GII (infected & treated with Mirazid®), GIII (infected & treated with Pentoxifylline®) and GIV (infected & treated with a combination of Mirazid and Pentoxifylline). Each group was further subdivided into 2 subgroups; subgroup ‘a’ which started treatment at 6th week post-infection (P.I.) and sacrificed at the end of 9th week P.I and subgroup ‘b’ which started treatment at 14th week P.I and sacrificed at the end of 17th week P.I. The efficacy of the treatment was assessed by histopathological examination of the liver with measurement of granuloma sizes, estimation of hydroxyproline content in the liver, and assessment of serum levels of leptin and transforming growth factor- ß1 (TGF- ß1) Mirazid (MZD) caused significant reductions in granuloma sizes and hepatic hydroxyproline content and caused non-significant reductions in serum levels of leptin and transforming growth factor- ß1 at 9th & 17th weeks P.I (GII). Pentoxifylline (PTX) caused significant reductions in granuloma sizes, hepatic hydroxyproline, and serum levels of leptin and transforming growth
factor- ß1 at the 9th & 17th weeks P.I (GIII). While combined therapy of both MZD & PTX in GIV caused more reductions in granuloma sizes, hepatic hydroxyproline, and serum levels of leptin and TGF- ß1 at the 9th & 17th weeks P.I when compared to the other groups.

Keywords